Dr. Isufi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
# Yale
New Haven, CT 06510Phone+1 646-943-4060Fax+1 203-200-2026
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
Stony Brook University Health Sciences Center School of MedicineClass of 2004
Certifications & Licensure
CT State Medical License 2011 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Start of enrollment: 2016 Oct 01
- Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Start of enrollment: 2019 Apr 16
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
Roles: Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Addressing platelet insecurity - A national call to action.Eric A Gehrie, Pampee P Young, Sridhar V Basavaraju, Arthur W Bracey, Andrew P Cap
Transfusion. 2024-10-01 - Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.Rachael Straining, Francine Foss, Molly Schiffer, Kejal Amin, Sonal Agarwal
Clinical Lymphoma, Myeloma & Leukemia. 2024-09-08 - Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas.Mengyang Di, Kunal C Potnis, Jessica B Long, Iris Isufi, Francine Foss
JNCI Cancer Spectrum. 2024-07-01
Abstracts/Posters
- A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...Iris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell LymphomaIris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell TransplantationIris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology MeetingNovember 26th, 2024- Smilow Cancer Hospital Cellular Therapies ProgramJuly 30th, 2024
- Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
